Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2C1YN)

Drug Name

MEGF0444A Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Metastatic colorectal cancer	2B91	Phase 2	[1]
Non-small-cell lung cancer	2C25.Y	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Epidermal growth factor-like protein 7 (EGFL7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anti-EGFL7	DM0ZDJ5	Non-small-cell lung cancer	2C25.Y	Phase 1	[3]
RG7414	DMCQRS2	Colorectal cancer	2B91.Z	Discontinued in Phase 2	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor-like protein 7 (EGFL7)	TT7WD0H	EGFL7_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00909740) A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
2	A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) May 2011 vol.29 no.15_suppl 2614.
3	Clinical pipeline report, company report or official report of Genentech (2009).
4	Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. J Clin Invest. 2013 September 3; 123(9): 3997-4009.